Novo Nordisk shares retreat after ADA conference updates fail to excite investors (NVO)
chart down red arrow NEW SIZE ©Shutterstock Novo Nordisk (NYSE:NVO) shares fell 3% on Monday as investors digested…
First Dual GLP-1/GIP Receptor Agonist Developed for Type 1 Diabetes Shows Promising Benefits in Blood Glucose Control
Phase 2 Study Results Highlight Use of Once-Daily Injection for Weight Loss and Reduction in Insulin Use NEW…
Eli Lilly weight loss drug data supports long-term obesity market position, says UBS
Eli Lilly weight loss drug data supports long-term obesity market position, says UBS Proactive uses images sourced from…